Abstract
Since the first demonstration by Mazzaferri and colleagues1 that the administration of radioiodine therapy after total thyroidectomy for differentiated thyroid cancer reduced mortality and recurrences, such treatment strategy became the standard of care for patients with thyroid cancer. At that time, no distinction was made regarding clinical, pathological, or radiological features. Subsequently, the same authors2 reported that postoperative thyroid ablation with radioiodine was mostly effective in stage II and III disease and that 1·1 GBq (30 mCi) doses were as effective as 3·7 GBq (100 mCi) doses.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
